A Phase II Study Combining PEGPH20 With Concurrent Gemcitabine and Radiotherapy in Patients With Localized, Unresectable Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Hyaluronidase (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms HALO-IST
- 14 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 18 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.